Impact of different PSMA PET-based eligibility criteria on outcome of [¹⁷⁷Lu]Lu-PSMA radioligand therapy using [¹⁸F]rhPSMA-7/[¹⁸F]rhPSMA-7.3 (Flotufolastat).

Authors

Sonia Grigorascu, Thomas Langbein, Isabel Rauscher, Kimberley Hansen, Theo Lorenzini, Wolfgang A Weber, Türkay Hekimsoy, Lena Unterrainer, Matthias Eiber

Published in

EJNMMI research. Jun 18, 2026. Epub Jun 18, 2026.

Abstract

[¹⁷⁷Lu]Lu-PSMA radioligand therapy (RLT) is key in treating metastatic castration-resistant prostate cancer (mCRPC). Various PSMA agents and eligibility criteria for [¹⁷⁷Lu]Lu-PSMA RLT have been described. We retrospectively assessed applicability and outcomes using Blue Earth Therapeutics' (BET) phase I study criteria with [¹⁸F]rhPSMA-7 and Flotufolastat ([¹⁸F]rhPSMA-7.3), comparing them to VISION trial-based PSMA PET/CT criteria. Patients eligible for [¹⁷⁷Lu]Lu-PSMA RLT, as assessed by an interdisciplinary board, were retrospectively stratified into four groups based on whether their PSMA PET scans with Flotufolastat met BET (B + /B-) and/or VISION (V + /V-) criteria. Outcome parameters like PSA response, PSA progression-free survival (PSA-PFS), and overall survival (OS) were compared, and reasons for (in-)eligibility by BET or VISION were analyzed.
In total, 191 mCRPC patients from our institutional database were included, of which 138 underwent [¹⁸F]rhPSMA-7.3 and 53 [¹⁸F]rhPSMA-7. 161 (84.3%) met both criteria (V + /B +), 13 (6.8%) were ineligible (V-/B-), and 17 (8.9%) met VISION but not BET criteria (V + /B-). No patient was BET-eligible without also fulfilling VISION criteria. Of the 30 patients excluded by BET criteria, 17 (56.7%) lacked the "majority" tumor volume criterion; 10/13 (76.9%) excluded by VISION had visceral metastases with lower PSMA expression than the liver. In the subgroups V + /B + , V + /B-, and V-/B-, a PSA response > 50% was present in 62/157 (39.5%), 2/17 (11.8%), and 0/13 (0%) patients, respectively. V + /B + patients had the significantly longest PSA-PFS compared to V + /B- and V-/B- (PSA-PFS: 4.3 months (95% CI 3.4 - 5.2) vs. 1.5 months (95% CI 1.4 - 1.6) vs. 2.8 months (95% CI 0.0 - 6.5), p = 0.002) and a trend towards longer OS (14.9 vs. 13.1 vs. 7.7 months, p = 0.065).
Multiple similarities between BET and VISION eligibility criteria (V + /B +) prior to [¹⁷⁷Lu]Lu-PSMA RLT were observed, with the majority of patients fulfilling both. Positivity in both criteria was associated with the best outcome. Data from our pilot cohort suggest that the criteria for BET's phase I trial select patients more strictly for [¹⁷⁷Lu]Lu-PSMA RLT than VISION criteria, while OS did not significantly differ between the three different groups.

PMID:
42313302
Bibliographic data and abstract were imported from PubMed on 18 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.